- Raised funding round led by NGT HealthCare II, May 2023
About
EMRIS Pharma is developing a novel small molecule topically administrated for the prevention of skin toxicities induced by EGFR inhibitors (EGFRi). This innovative therapy intends to improve cancer patients’ quality of life and compliance with cancer therapy.
Current treatment strategies and new developments focus on symptom reduction post-EGFR inhibition when our solution blocks the initial trigger causing skin toxicity, the drug-receptor interaction. The company new approach will prevent skin toxicity, enabling more cancer patients to go about their daily lives without compromising their anticancer treatment.
Its solution (SDT 011) is targeting a huge market with global unmet need. The market is also expected to substantially grow due to new combinations of cancer treatments with EGFRi and a potential product approval of new EGFRi bi-specific antibodies.
SDT 011 (EMR-001) is the first-to-market product in the pipeline of the company. Additional new candidate compounds are currently in development for Tyrosine Kinase Inhibitors’ induced skin toxicities that can substantially contribute to the market size.
Funding history · 1 round · — total
Q&A
- What is Emris Pharma's primary focus?
- Emris Pharma is developing a novel small molecule, topically administered, to prevent skin toxicities caused by EGFR inhibitors (EGFRi) in cancer patients.
- When was Emris Pharma founded?
- Emris Pharma was founded in May 2023.
- What is the current employee count at Emris Pharma?
- Emris Pharma has 6 employees, falling within the 1-10 employee bucket.
- Which investors participated in Emris Pharma's funding round in May 2023?
- In May 2023, Emris Pharma received funding from NGT HealthCare II and Israel Innovation Authority.
- What is the current stage of Emris Pharma's product development?
- Emris Pharma's product, SDT 011 (EMR-001), is currently in the R&D stage.
- What is Emris Pharma's primary sector?
- Emris Pharma's primary sector is Health Tech & Life Sciences.
- Does Emris Pharma hold any patents?
- Yes, Emris Pharma holds 1 patent.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | emris-pharma.com/ |
|---|---|
| linkedin.com/company/93267280 |
Identifiers & details
| Founded | 2023-5 |
|---|---|
| Employees (exact) | 6 |
Radar intelligence
Patents
| EPO | 1 |
|---|
Web history (Wayback)
| Domain | emris-pharma.com |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|